Biosensors International Group to appoint Prof Keith Oldroyd as Chief Medical Officer

Morges, June 02 2020 – Biosensors International Group is delighted to announce the appointment of **Prof Keith G Oldroyd MBChB; MD(Hons); FRCP(Glasg); FESC** to the post of Chief Medical Officer.

Prior to taking up his new post, Prof Oldroyd was a Consultant Interventional Cardiologist at the West of Scotland Regional Heart and Lung Centre in the Golden Jubilee National Hospital, Glasgow, UK and has a career experience of more than 9000 PCI procedures. He also has significant experience of both TAVI and Mitraclip procedures.

Prof Oldroyd holds a personal chair within the Institute of Cardiovascular and Medical Sciences, University of Glasgow and was the NHS Scotland Research Lead for CV Disease. His own research interests include the clinical and experimental assessment of novel drug eluting stents and the use of invasive physiological indices of stenosis severity to guide decision making in the cath lab. He has been a principal investigator in several international trials including FAME, FAME 2, PRAMI, LEADERS FREE, CULPRIT SHOCK and TWILIGHT all of which have been published in the New England Journal of Medicine. In 2018 he received a Lifetime Achievement Award from the British Cardiovascular Intervention Society and in 2019 the Sir James McKenzie Medal from the British Cardiovascular Society.

"*I have had an extraordinarily happy and fulfilling career in interventional cardiology and I pay testament to all of my colleagues in the NHS, both past and present. However, it's time to move on and I am delighted to be joining Biosensors at such a pivotal moment in the company's development. Biosensors have a history of innovative drug and device development having pioneered the use of both biodegradable polymer and polymer free Biolimus A9™ eluting coronary stents. They have also facilitated guideline changing clinical trials such as LEADERS FREE which focussed the minds of clinicians on the very poor outcomes after PCI in patients with High Bleeding Risk (HBR) and demonstrated how these could be dramatically improved by the use of the BioFreedom™ stent and very short duration DAPT. Moving forward, Biosensors are actively studying a Biolimus coated balloon for use in PCI and are expanding into the rapidly growing field of structural heart disease intervention through the acquisition of New Valve Technology (NVT AG), the developers of the ALLEGRA™ TAVI device. The most exciting aspect of this next phase of my career is the opportunity to work with the world class team of engineers, designers and researchers assembled by Biosensors and of course the clinicians with whom the company collaborates in its clinical research programme*"; Prof Oldroyd declared.

About Biosensors International Group

Biosensors Intl. is a subsidiary of Blue Sail Medical, with 25 years experience in designing, manufacturing, and marketing innovative medical devices that improve patients' lives, including devices for Percutaneous Coronary Intervention. The company has worldwide operations, and with the combination of direct sales teams and a worldwide distribution networks, it serves the needs of the healthcare community.

For more information about Biosensors Intl., please visit: https://www.biosensors.com/intl/

About Blue Sail Medical (SZ.002382)

Blue Sail Medical has established a development strategy in cardiovascular and cerebrovascular diseases area. The company focuses on both high value consumables (cardiovascular and interventional cardiac surgery related devices), and low/medium value consumables (medical gloves, health protective gloves, first aid kits, medical dressings). The acquisition of NVT will capture a great M&A opportunity for Blue Sail Medical to obtain quality assets in the TAVI business.

For more information about Blue Sail Medical, please visit
http://www.bluesail.cn/en/index.php